

PCT
RECEIVED
TECH CENTER 1000
JUN 17 2003FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:
ST98046USPCTApplicants:
HERSCOVICI ET AL.Serial No.
09/857,008Filing Date:
February 22, 2002

Title of Invention:

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner of Patents, P.O. Box 1450, Arlington, VA 22313-1450, at 703 746-6196, on

Date of Deposit: May 16, 2003

Printed Name of Person Signing Certificate: Delia Coppola
Signature: Delia Coppola

Total Number of Pages Sent: 4

Attorney: W.C. Coppola

Group Art Unit: 1642

Examiner: Unknown

NOVEL NUCLEIC ACID TRANSFERRINGAGENTS, COMPOSITIONS CONTAINING THEM AND USES

TO: Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

<input type="checkbox"/> Amendment, 37 CFR _____	<input type="checkbox"/> Fee Transmittal
<input type="checkbox"/> Charge deposit account, in duplicate	<input type="checkbox"/> Petition under 37 CFR _____
<input type="checkbox"/> Extension of Time Petition	<input type="checkbox"/> Other _____
<input type="checkbox"/> Issue Fee Transmittal & Advance Order	<input checked="" type="checkbox"/> Other <u>Request For Corrected Filing Receipt</u>
<input type="checkbox"/> Maintenance Fee Transmittal	

Receipt Confirmed:

Cited

Lated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A.

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of
HERSCOVICI ET AL.

Examiner: **Unknown**Application No.: **09/857,008**Art Unit: **1642**Filed: **February 22, 2002**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P. O. Box 1450, Alexandria, VA 22313-1450,
at (703) 746-9195, on

Title: **NOVEL NUCLEIC ACID
TRANSFERRINGAGENTS,
COMPOSITIONS CONTAINING
THEM AND USES**

May 16, 2003
Date of Deposit
William C. Coppola
Signature

REQUEST FOR CORRECTED FILING RECEIPT


Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that under Foreign Applications the filing date for FR 98/15309 is listed as October 3, 1998. The correct date is December 3, 1998 as stated on the Declaration. The correction is not due to any error by Applicants and no fee is due.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

2025 RELEASE UNDER E.O. 14176



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP/ART UNIT	FILED REC'D	ATTY/DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/857,008	02/22/2002	1642	137256728	8795046 US PCT	3	32	1

005487
ROSS J Oehler
AVENTIS PHARMACEUTICALS INC.
ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER, NJ 08807
DUE DATE
ATTY

ACTION DUE Send filing receipt
form letter
3-24-03
Re 3-11-03
SWC

CONFIRMATION NO. 9262
FILING RECEIPT



"0C000000009582109"

Date Mailed: 03/04/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jean Herscovici, Paris, FRANCE;
Hans Hofland, Foster City, CA;
Christophe Jacopin, Sainte Genevieve des Bois, FRANCE;
Daniel Scherman, Paris, FRANCE;

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/FR99/02995 12/02/1999
which claims benefit of 60/117,184 01/26/1999

Foreign Applications

FRANCE 98/15309 10/03/1998 12/03/1998

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Requested

Title

Novel nucleic acid transferring agents, compositions containing them and uses

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12. If a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).